Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

NCT06022289 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
FGF Receptor Gene Mutation
FGF Amplification
FGF Receptor Gene Family Rearrangement
FGF Receptor Gene Translocation

Interventions

DRUG: Pemigatinib

Sponsor

Tianjin Medical University Second Hospital